Literature DB >> 28913611

Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography.

Philip Hoelter1, Stefan Lang2, Marina Weibart2, Manuel Schmidt2, Michael F X Knott2, Tobias Engelhorn2, Marco Essig3, Stephan Kloska2, Arnd Doerfler2.   

Abstract

PURPOSE: Gadobutrol (GB) is reported to provide improved relaxivity and concentration compared to gadoterate (GT). This study was designed to intraindividually compare quantitative and qualitative enhancement characteristics of GB to GT in cervicocranial magnetic resonance angiography (MRA) of patients with cerebrovascular disease (CVD).
METHODS: Patients (n = 54) with CVD underwent two identical contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of the cervical and intracranial vasculature in randomized order, using GB and GT in equimolar dose. Signal-to-noise ratios (SNR) and contrast-to-noise ratios (CNR) were obtained by two independent neuroradiologists, blinded to the applied contrast agents. Qualitative assessment was performed using a three-point scale with a focus on M1/M2 segments.
RESULTS: One thousand and twenty-six vessel segments were analyzed. GB revealed a significantly higher SNR (p = 0.032) and CNR (p = 0.031) in all vessel segments. GB featured a significantly higher SNR and CNR in thoracic (p = 0.022; p = 0.016) and cervical vessels (p = 0.03; p = 0.038), as well as in the posterior circulation (p = 0.012; p = 0.005). In blinded qualitative assessment, overall preference was given to GB (p = 0.02), showing a significant better delineation of the M1/M2 segments (p = 0.041).
CONCLUSION: Compared to GT, the use of GB results in a significantly higher SNR and CNR in cervical and cerebral CE-MRA, leading to a better delineation of the intracranial vasculature. Present results underline the potential of GB for improved CE-MRA assessment of vasculature in CVD patients.

Entities:  

Keywords:  Cerebrovascular disorders; Contrast media; Contrast-enhanced MR angiography (CE-MRA); Cranial vasculature; Diagnostic imaging

Mesh:

Substances:

Year:  2017        PMID: 28913611     DOI: 10.1007/s00234-017-1922-z

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  24 in total

1.  Contrast material-enhanced MRA overestimates severity of carotid stenosis, compared with 3D time-of-flight MRA.

Authors:  Tiffany C Townsend; David Saloner; Xian Mang Pan; Joseph H Rapp
Journal:  J Vasc Surg       Date:  2003-07       Impact factor: 4.268

Review 2.  Carotid-artery imaging in the diagnosis and management of patients at risk of stroke.

Authors:  Jean Marie U-King-Im; Victoria Young; Jonathan H Gillard
Journal:  Lancet Neurol       Date:  2009-06       Impact factor: 44.182

Review 3.  MR angiography and imaging for the evaluation of middle cerebral artery atherosclerotic disease.

Authors:  A J Degnan; G Gallagher; Z Teng; J Lu; Q Liu; J H Gillard
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-22       Impact factor: 3.825

4.  Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.

Authors:  Ulrike I Attenberger; Val M Runge; John N Morelli; Jonathan Williams; Carney B Jackson; Henrik J Michaely
Journal:  J Magn Reson Imaging       Date:  2010-03       Impact factor: 4.813

5.  MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.

Authors:  Marc Saake; Soenke Langner; Carsten Schwenke; Marina Weibart; Olav Jansen; Norbert Hosten; Arnd Doerfler
Journal:  Eur Radiol       Date:  2015-06-30       Impact factor: 5.315

Review 6.  Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol.

Authors:  Bernd Tombach; Walter Heindel
Journal:  Eur Radiol       Date:  2002-02-21       Impact factor: 5.315

7.  Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience.

Authors:  Mathias Goyen; Christoph U Herborn; Florian M Vogt; Knut Kröger; Rüdiger Verhagen; Fan Yang; Silke Bosk; Jörg F Debatin; Stefan G Ruehm
Journal:  J Magn Reson Imaging       Date:  2003-05       Impact factor: 4.813

8.  Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.

Authors:  Jens Harald Kramer; Elisabeth Arnoldi; Christopher J François; Andrew L Wentland; Konstantin Nikolaou; Bernd J Wintersperger; Thomas M Grist
Journal:  Invest Radiol       Date:  2013-03       Impact factor: 6.016

9.  Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography.

Authors:  Christoph U Herborn; Thomas C Lauenstein; Stefan G Ruehm; Silke Bosk; Jörg F Debatin; Mathias Goyen
Journal:  Invest Radiol       Date:  2003-01       Impact factor: 6.016

10.  1.0-M gadobutrol versus 0.5-M gadoterate for peripheral magnetic resonance angiography: a prospective randomized controlled clinical trial.

Authors:  Zsolt Szucs-Farkas; Johannes M Froehlich; Martin Ulrich; Hans-Ueli Wuersten; Dominique Guignard; Sandra Wyss; Marianne Braunschweig
Journal:  J Magn Reson Imaging       Date:  2008-06       Impact factor: 4.813

View more
  3 in total

1.  Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.

Authors:  Chau Hung Lee; Balamurugan Vellayappan; Matthias Taupitz; Bernd Hamm; Patrick Asbach
Journal:  Eur Radiol       Date:  2019-07-01       Impact factor: 5.315

Review 2.  Gadobutrol: A Review in Contrast-Enhanced MRI and MRA.

Authors:  Lesley J Scott
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

3.  Non-contrast mDixon MR angiography of the neck: Comparison with time-of-flight MR angiography in normal subjects.

Authors:  Tomohiro Mizoshiri; Morikatsu Yoshida; Seitaro Oda; Shota Tsumagari; Takeshi Nakaura; Kazunori Harada; Osamu Ikeda
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.